Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02625623 · ClinicalTrials.gov registry record · Phase 3
Avelumab in Third-Line Gastric Cancer (JAVELIN Gastric 300)
A Phase 3 study, sponsored by EMD Serono Research & Development Institute.
- Completed
- Registry status
- Phase 3
- Development phase
- 371
- Enrollment target
NCT02625623: Completed Phase 3 study, sponsored by EMD Serono Research & Development Institute.
NCT02625623 is a Phase 3 study that has completed, run by EMD Serono Research & Development Institute. The registered enrollment target is 371 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (52% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02625623, a Phase 3 study, has completed, sponsored by EMD Serono Research & Development Institute.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 371 participants
- Enrollment target
Study Summary
The purpose of this study was to demonstrate superiority of treatment with avelumab plus best supportive care (BSC) versus physician's choice (chosen from a pre-specified list of therapeutic options) plus BSC.
Primary Outcome
OS was defined as the time from randomization to the date of death due to any cause. For participants who were still alive at the time of data analysis or who were lost to follow-up, OS time was censored at the date of last contact. OS was measured using Kaplan-Meier (KM) estimates.
Interventions
- DRUG Paclitaxel
- DRUG Irinotecan
- DRUG Avelumab
- OTHER Best Supportive Care (BSC)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 371 participants |
| Start Date | 2015-12-28 |
| Est. Completion | 2019-11-13 |
| Phase | Phase 3 |
What the finished NCT02625623 record still lists
NCT02625623 is an interventional study that assigns participants to a tested intervention. The registered 371 participants enrollment target is mid-sized for trials with a published cap, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (52% lower).
The record links to 0 conditions, and to 4 interventions - of which Paclitaxel is the first listed.
NCT02625623 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02625623 about?
NCT02625623 is a clinical study titled "Avelumab in Third-Line Gastric Cancer (JAVELIN Gastric 300)". The purpose of this study was to demonstrate superiority of treatment with avelumab plus best supportive care (BSC) versus physician's choice (chosen from a pre-specified list of therapeutic options) plus BSC.
What is the current status of trial NCT02625623?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 371 participants. The study started on 2015-12-28. Estimated completion is 2019-11-13.
What interventions are being tested in trial NCT02625623?
The interventions under investigation include: Paclitaxel (DRUG), Irinotecan (DRUG), Avelumab (DRUG), Best Supportive Care (BSC) (OTHER).
Who is sponsoring clinical trial NCT02625623?
This trial is sponsored by EMD Serono Research & Development Institute, which has 81 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02625623's enrollment target sits among peer trials
371 992nd of 2000 higher than 1,008 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05743673 · 371 participants
SHAPE Test for Preoperative Risk Stratification
- NCT05761847 · 371 participants · NA
Pediatric Medication Therapy Management Trial
- NCT04801589 · 372 participants · Phase 3
Goal-Directed Sedation in Mechanically Ventilated Infants and Children
- NCT04879329 · 372 participants · Phase 2
A Study of Disitamab Vedotin Alone or With Pembrolizumab in Urothelial Cancer That Expresses HER2
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI